Xcout Intel
Prokarium
Prokarium is a biotechnology research company headquartered in London, United Kingdom, focused on developing targeted immunotherapies like its investigational treatment ZH9.
Subscribe to see Prokarium’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Prokarium at a glance
Prokarium is a healthcare company headquartered in United Kingdom. It has raised at least $45.7M across the 3 funding rounds on record. Its most recent funding round raised $30M in February 2023. Xcout tracks 6 named people at Prokarium, including Ibs Mahmood (CEO).
Prokarium leadership
- Ibs MahmoodCEO
- Dara HenryCOO
- Julia JonesCFO
- Josi HolzCMO
- Livija DebanCSO
- Nick GlanvilleVP of Research
Prokarium funding rounds
At least $45.7M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $30M | 2 named | |
| — | $5.7M | 1 named | |
| Series A | $10M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Prokarium competitors
A few of Prokarium's closest competitors — see the full list of competitors and alternatives →
PDC*line Pharma is a clinical-stage biotechnology company headquartered in Liège, Belgium, focused on developing innovative cell therapies and cancer vaccines.
Healome Therapeutics is an eye care therapeutics company headquartered in Birmingham, United Kingdom. The company focuses on developing more effective, safer, and practical treatments for vision-threatening ocular surface diseases.
Vantage Biosciences is a clinical-stage biotechnology company headquartered in London, United Kingdom. Founded in 2023, the firm focuses primarily on advancements and clinical trials in the field of ophthalmology. It manages drug pipelines and pharmaceutical research out of its London office.
Harbour BioMed is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology.
Zhejiang DTRM Biopharma Co. Ltd. is an oncology-focused biopharmaceutical company that develops, produces, and sells pharmaceutical products, including immunotherapy drugs and small molecule therapies for cancer and immune diseases. The company's pipeline features assets such as BTK inhibitors and combination therapies.
Get Prokarium's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Prokarium in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access